Tear Sheet

Company Overview

HTG’s mission is to advance the promise of precision medicine through innovative transcriptome-wide profiling technology designed to accelerate the development of diagnostics and hasten the discovery of novel drug candidates to effect lifechanging outcomes. Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG’s proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery. 

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

Date Title and Summary
Toggle Summary HTG to Sponsor Keynote Presentation Featuring Customer Use of its HTG EdgeSeq Technology in Clinical Trials
TUCSON, Ariz. , June 08, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced that it will be sponsoring a keynote presentation at the 7 th Annual
Toggle Summary HTG Technology Featured in Multiple Scientific Abstracts Highlighting Novel Applications in Precision Medicine at ASCO 2022
TUCSON, Ariz. , June 06, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced its HTG EdgeSeq technology was highlighted in multiple
Toggle Summary HTG to Host Scientific Webinar Featuring Customer Use of the HTG Transcriptome Panel in Preclinical and Clinical Programs
TUCSON, Ariz. , June 01, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced that it will be hosting a scientific webinar titled “Integration of
Toggle Summary HTG Molecular Diagnostics to Participate in the H.C. Wainwright Global Investment Conference
TUCSON, Ariz. , May 17, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that management will participate virtually in the H.C.
Toggle Summary HTG Molecular Diagnostics Reports First Quarter 2022 Results
Call scheduled for today, May 12, at 4:30 pm ET TUCSON, Ariz. , May 12, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today reported recent business

Stock Chart

SEC Filings

Filing date Description

Report of unscheduled material events or corporate event

A preliminary proxy statement providing notification matters to be brought to a vote

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities